监测代谢功能障碍相关脂肪性肝病的疾病进展
本综述检索PubMed至2023年8月15日,纳入101篇英文文献,探讨监测MASLD疾病进展与治疗反应的方法,指出多种生物标志物可用于不同诊疗场景,但需进一步研究以更有效验证无创检测。
要点
- MASLD是最常见的慢性肝病,其患病率随肥胖和代谢综合征流行而上升。
- MASLD进展为MASH和晚期纤维化可导致失代偿期肝硬化及肝相关事件、肝细胞癌和死亡。
- 多种生物标志物可用于不同诊疗场景监测疾病进展,但需进一步研究以更有效验证无创检测。
核心结论
- 多种生物标志物可用于不同诊疗场景监测MASLD疾病进展。
- 需进一步研究以更有效地验证无创检测。
研究设计与样本
- 综述检索PubMed自建库至2023年8月15日,使用MASLD、MASH、NAFLD、NASH、生物标志物、临床试验等MeSH词,并检索作者文件,仅纳入英文文献,最终基于原创性和相关性生成参考文献列表,共引用101篇参考文献。
主要发现
- MASLD是最常见的慢性肝病,其患病率随肥胖和代谢综合征流行而增加。
- MASLD进展为MASH和晚期纤维化可导致失代偿期肝硬化及肝相关事件、肝细胞癌和死亡。
- 监测疾病进展对降低发病率、死亡率、移植需求和经济负担至关重要。
- 在FDA批准药物可用后评估治疗反应仍是未满足的临床需求。
临床怎么用
- 原文未据此给出推荐。
局限性
- 需进一步研究以更有效地验证无创检测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common cause of chronic liver disease. Its prevalence is increasing with the epidemic of obesity and metabolic syndrome. MASLD progression into metabolic dysfunction-associated steatohepatitis (MASH) and advanced fibrosis may lead to decompensated cirrhosis and development of liver-related events, hepatocellular carcinoma and death. Monitoring disease progression is critical in decreasing morbidity, mortality, need for transplant and economic burden. Assessing for treatment response once FDA-approved medications are available is still an unmet clinical need. AIMS: To explore the most up-to-date literature on testing used for monitoring disease progression and treatment response METHODS: We searched PubMed from inception to 15 August 2023, using the following MeSH terms: 'MASLD', 'Metabolic dysfunction-associated steatotic liver disease', 'MASH', 'metabolic dysfunction-associated steatohepatitis', 'Non-Alcoholic Fatty Liver Disease', 'NAFLD', 'non-alcoholic steatohepatitis', 'NASH', 'Biomarkers', 'clinical trial'. Articles were also identified through searches of the authors' files. The final reference list was generated based on originality and relevance to this review's broad scope, considering only papers published in English. RESULTS: We have cited 101 references in this review detailing methods to monitor MASLD disease progression and treatment response. CONCLUSION: Various biomarkers can be used in different care settings to monitor disease progression. Further research is needed to validate noninvasive tests more effectively.
引用
- Noureddin N, Copur-Dahi N, Loomba R, et al. Monitoring disease progression in metabolic dysfunction-associated steatotic liver disease. Aliment Pharmacol Ther. 2024. PMID: 38813822. doi:10.1111/apt.17752
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。